HCW Biologics Inc. (HCWB) |
|
1.91 -0.05 (-2.55%)
|
09-28 16:00 |
|
Open: |
1.92 |
Pre. Close: |
1.96 |
|
High:
|
1.935 |
Low:
|
1.9 |
|
Volume:
|
2,299 |
Market Cap:
|
69(M) |
|
|
|
Technical analysis |
as of: 2023-09-28 4:51:01 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, upgraded from strong sell. Downward movement continues, but could change at any time. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 2.35 One year: 2.54 |
| Support: |
Support1: 1.75 Support2: 1.45 |
| Resistance: |
Resistance1: 2.01 Resistance2: 2.18 |
| Pivot: |
2.03 |
| Moving Average: |
MA(5): 1.99 MA(20): 1.99
MA(100): 1.96 MA(250): 1.92 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 40.6 %D(3): 52.8 |
| RSI: |
RSI(14): 43.8 |
| 52-week: |
High: 2.59 Low: 1.08 |
| Average Vol(K): |
3-Month: 9 (K) 10-Days: 11 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HCWB ] has closed above bottom band by 0.1%. Bollinger Bands are 26.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.94 - 1.95 |
1.95 - 1.96 |
|
Low:
|
1.87 - 1.88 |
1.88 - 1.89 |
|
Close:
|
1.89 - 1.91 |
1.91 - 1.93 |
|
Company Description |
|
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida. |
Headline News |
Wed, 06 Sep 2023
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023 - Yahoo Finance
Fri, 18 Aug 2023
Corvus stock gains as Oppenheimer starts with a bullish view - Seeking Alpha
Fri, 11 Aug 2023
HCW Biologics Reports Second Quarter 2023 Financial Results and ... - BioSpace
Fri, 21 Jul 2023
Michael Okunewitch's Stock Ratings - Maxim Group Analyst - Benzinga
Thu, 20 Jul 2023
Eliem stock gains on plans for strategic alternatives - Seeking Alpha
Fri, 28 Apr 2023
Longevity investment bulletin: Therini Bio, Calico, Alchemab and more - Longevity.Technology
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
50.4 (%) |
|
% Held by Institutions
|
2.4 (%) |
|
Shares Short
|
21 (K) |
|
Shares Short P.Month
|
23 (K) |
Stock Financials |
|
EPS
|
-0.5 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.8 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-512.7 |
|
Return on Assets (ttm)
|
-28.2 |
|
Return on Equity (ttm)
|
-50.1 |
|
Qtrly Rev. Growth
|
37.2 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.1 |
|
EBITDA (p.s.)
|
-0.52 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-19 (M) |
Stock Valuations |
|
PE Ratio
|
-3.82 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.38 |
|
Price to Sales
|
17.96 |
|
Price to Cash Flow
|
-3.59 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
